Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized …
FX Pi-Sunyer, LJ Aronne, HM Heshmati, J Devin… - Jama, 2006 - jamanetwork.com
ContextRimonabant, a selective cannabinoid-1 receptor blocker, may reduce body weight
and improve cardiometabolic risk factors in patients who are overweight or obese.
ObjectiveTo compare the efficacy and safety of rimonabant with placebo each in conjunction
with diet and exercise for sustained changes in weight and cardiometabolic risk factors over
2 years. Design, Setting, and ParticipantsRandomized, double-blind, placebo-controlled trial
of 3045 obese (body mass index≥ 30) or overweight (body mass index> 27 and treated or …
and improve cardiometabolic risk factors in patients who are overweight or obese.
ObjectiveTo compare the efficacy and safety of rimonabant with placebo each in conjunction
with diet and exercise for sustained changes in weight and cardiometabolic risk factors over
2 years. Design, Setting, and ParticipantsRandomized, double-blind, placebo-controlled trial
of 3045 obese (body mass index≥ 30) or overweight (body mass index> 27 and treated or …